Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infection or Inflammation Clear all
Recruiting Phase 4 Interventional

Early Versus Late Adjunctive Vasopressin in Septic Shock

NCT06709573
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
vasopressin - early initiation, vasopressin - standard initiation
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 2 Interventional

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

NCT00879606
View directory record Official record
Conditions
Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
ALT-836, Placebo
Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
20
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 17, 2026, 9:35 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Split Scar Study to Assess Cosmetic Outcome From Differing Suture Spacing

NCT03284983
View directory record Official record
Conditions
Suture, Complication, Wound, Wound Complication, Wound Dehiscence, Wound of Skin, Surgery, Suture; Complications, Infection or Inflammation
Interventions
Suture spacing for wound closure
Other
Lead sponsor
Silver Falls Dermatology
Other
Eligibility
30 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salem, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 17, 2026, 9:35 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Histological Analysis of AlloMend® Acellular Dermal Matrix Used in Breast Implant Surgeries

NCT05744414
View directory record Official record
Conditions
Breast Implant; Complications, Infection or Inflammation
Interventions
Not listed
Lead sponsor
AlloSource
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 17, 2026, 9:35 PM EDT
Recruiting Phase 4 Interventional

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema

NCT07095361
View directory record Official record
Conditions
Pleural Infection Bacterial, Pleural Infections, Pleural Infections and Inflammations, Empyema, Pleural, Empyema, Complicated Pleural Effusion/ Empyema, Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion
Interventions
Fibrinolytic once daily, Fibrinolytic twice daily, DNA degradation once daily, DNA degradation twice daily
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
New Haven, Connecticut • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Enrolling by invitation No phase listed Observational

Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders

NCT00001351
View directory record Official record
Conditions
Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 4 Interventional Results available

Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch

NCT01411891
View directory record Official record
Conditions
Catheter Infections, Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Interventions
Chlorhexidine impregnated patch (Biopatch)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 17, 2026, 9:35 PM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Cooperstown, New York • Winston-Salem, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 3 Interventional Results available

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

NCT03434028
View directory record Official record
Conditions
Septic Shock
Interventions
Early Vasopressors, Early Fluids
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
50
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 17, 2026, 9:35 PM EDT
Not listed No phase listed Observational

Study of Treatment's Echocardiographic Mechanisms

NCT03913403
View directory record Official record
Conditions
Sepsis
Interventions
ECHO, Blood Draw
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Boston, Massachusetts • The Bronx, New York • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Not applicable Interventional

Non-Invasive Cardiac Output Monitor (NICOM) for Goal-directed Fluid Resuscitation for Inpatients With Hypotension and/or Septic Shock

NCT05630716
View directory record Official record
Conditions
Sepsis, Hypotension, Septic Shock
Interventions
NICOM
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 17, 2026, 9:35 PM EDT
Completed No phase listed Observational

Procalcitonin Monitoring Sepsis Study

NCT01523717
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Brahms AG
Industry
Eligibility
18 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Sacramento, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 17, 2026, 9:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2

NCT02073760
View directory record Official record
Conditions
Cardiovascular Disease, Healthcare Associated Infectious Disease, Sternal Superficial Wound Infection, Deep Sternal Infection, Mediastinitis, Thoracotomy, Conduit Harvest or Cannulation Site, Sepsis, Pneumonia
Interventions
There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 17, 2026, 9:35 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Physiologic State Intelligence Study

NCT07814118
View directory record Official record
Conditions
Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions
OMNIPHYS Multimodal Ultrasound Imaging System
Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2046
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Completed No phase listed Observational Results available

Home Away From Home - Medical Outcomes

NCT02774850
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Bacteremia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 19 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 3 Interventional

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

NCT00105144
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
62
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 3 Interventional

Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants

NCT00005775
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions
Glutamine, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
1,433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
15
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 17, 2026, 9:35 PM EDT